ALKERMES PLC (ALKS) Stock Fundamental Analysis

NASDAQ:ALKS • IE00B56GVS15

30.21 USD
-0.52 (-1.69%)
Last: Feb 27, 2026, 01:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to ALKS. ALKS was compared to 521 industry peers in the Biotechnology industry. ALKS has an excellent financial health rating, but there are some minor concerns on its profitability. ALKS has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • ALKS had positive earnings in the past year.
  • In the past year ALKS had a positive cash flow from operations.
  • In multiple years ALKS reported negative net income over the last 5 years.
  • ALKS had a positive operating cash flow in 4 of the past 5 years.
ALKS Yearly Net Income VS EBIT VS OCF VS FCFALKS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 14.57%, ALKS belongs to the top of the industry, outperforming 95.39% of the companies in the same industry.
  • With an excellent Return On Equity value of 19.58%, ALKS belongs to the best of the industry, outperforming 95.59% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 16.22%, ALKS belongs to the best of the industry, outperforming 96.35% of the companies in the same industry.
Industry RankSector Rank
ROA 14.57%
ROE 19.58%
ROIC 16.22%
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
ALKS Yearly ROA, ROE, ROICALKS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 22.30%, ALKS belongs to the top of the industry, outperforming 94.24% of the companies in the same industry.
  • The Operating Margin of ALKS (23.59%) is better than 95.39% of its industry peers.
  • ALKS has a better Gross Margin (86.04%) than 88.68% of its industry peers.
  • ALKS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 23.59%
PM (TTM) 22.3%
GM 86.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
ALKS Yearly Profit, Operating, Gross MarginsALKS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ALKS is creating value.
  • There is no outstanding debt for ALKS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALKS Yearly Shares OutstandingALKS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ALKS Yearly Total Debt VS Total AssetsALKS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 6.45 indicates that ALKS is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.45, ALKS is in the better half of the industry, outperforming 75.05% of the companies in the same industry.
  • ALKS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.45
ROIC/WACC2.06
WACC7.86%
ALKS Yearly LT Debt VS Equity VS FCFALKS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • ALKS has a Current Ratio of 3.67. This indicates that ALKS is financially healthy and has no problem in meeting its short term obligations.
  • ALKS has a Current ratio of 3.67. This is comparable to the rest of the industry: ALKS outperforms 44.53% of its industry peers.
  • ALKS has a Quick Ratio of 3.27. This indicates that ALKS is financially healthy and has no problem in meeting its short term obligations.
  • ALKS has a Quick ratio (3.27) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.67
Quick Ratio 3.27
ALKS Yearly Current Assets VS Current LiabilitesALKS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for ALKS have decreased strongly by -34.90% in the last year.
  • ALKS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 34.43% yearly.
EPS 1Y (TTM)-34.9%
EPS 3Y77.08%
EPS 5Y34.43%
EPS Q2Q%-56.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-10.57%

3.2 Future

  • Based on estimates for the next years, ALKS will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.40% on average per year.
  • The Revenue is expected to grow by 10.44% on average over the next years. This is quite good.
EPS Next Y-20.69%
EPS Next 2Y-9.41%
EPS Next 3Y3.97%
EPS Next 5Y8.4%
Revenue Next Year23.02%
Revenue Next 2Y12.82%
Revenue Next 3Y10.55%
Revenue Next 5Y10.44%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ALKS Yearly Revenue VS EstimatesALKS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
ALKS Yearly EPS VS EstimatesALKS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • ALKS is valuated correctly with a Price/Earnings ratio of 15.98.
  • 95.01% of the companies in the same industry are more expensive than ALKS, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 27.11, ALKS is valued a bit cheaper.
  • Based on the Price/Forward Earnings ratio of 20.18, the valuation of ALKS can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ALKS indicates a rather cheap valuation: ALKS is cheaper than 92.90% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.13, ALKS is valued a bit cheaper.
Industry RankSector Rank
PE 15.98
Fwd PE 20.18
ALKS Price Earnings VS Forward Price EarningsALKS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ALKS is valued cheaper than 97.50% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALKS indicates a rather cheap valuation: ALKS is cheaper than 98.27% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 10.15
EV/EBITDA 8.91
ALKS Per share dataALKS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • ALKS has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.46
EPS Next 2Y-9.41%
EPS Next 3Y3.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ALKS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALKERMES PLC

NASDAQ:ALKS (2/27/2026, 1:16:03 PM)

30.21

-0.52 (-1.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-29
Inst Owners105.82%
Inst Owner Change1.64%
Ins Owners1.48%
Ins Owner Change5.39%
Market Cap4.99B
Revenue(TTM)N/A
Net Income(TTM)339.32M
Analysts80.87
Price Target44.69 (47.93%)
Short Float %11.74%
Short Ratio10.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.1%
Min EPS beat(2)59.84%
Max EPS beat(2)72.36%
EPS beat(4)4
Avg EPS beat(4)43.68%
Min EPS beat(4)12.02%
Max EPS beat(4)72.36%
EPS beat(8)4
Avg EPS beat(8)10.27%
EPS beat(12)8
Avg EPS beat(12)42.89%
EPS beat(16)11
Avg EPS beat(16)151.46%
Revenue beat(2)2
Avg Revenue beat(2)10.32%
Min Revenue beat(2)8.51%
Max Revenue beat(2)12.13%
Revenue beat(4)3
Avg Revenue beat(4)7.62%
Min Revenue beat(4)-1.19%
Max Revenue beat(4)12.13%
Revenue beat(8)4
Avg Revenue beat(8)3.11%
Revenue beat(12)7
Avg Revenue beat(12)3.8%
Revenue beat(16)10
Avg Revenue beat(16)3.09%
PT rev (1m)0.29%
PT rev (3m)0.57%
EPS NQ rev (1m)-1.13%
EPS NQ rev (3m)-3.14%
EPS NY rev (1m)-0.46%
EPS NY rev (3m)-0.83%
Revenue NQ rev (1m)0.1%
Revenue NQ rev (3m)0.48%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.2%
Valuation
Industry RankSector Rank
PE 15.98
Fwd PE 20.18
P/S 3.28
P/FCF 10.15
P/OCF 9.23
P/B 2.88
P/tB 3.02
EV/EBITDA 8.91
EPS(TTM)1.89
EY6.26%
EPS(NY)1.5
Fwd EY4.96%
FCF(TTM)2.98
FCFY9.85%
OCF(TTM)3.27
OCFY10.84%
SpS9.21
BVpS10.5
TBVpS9.99
PEG (NY)N/A
PEG (5Y)0.46
Graham Number21.13
Profitability
Industry RankSector Rank
ROA 14.57%
ROE 19.58%
ROCE 19.34%
ROIC 16.22%
ROICexc 40.45%
ROICexgc 45.58%
OM 23.59%
PM (TTM) 22.3%
GM 86.04%
FCFM 32.29%
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 163.07%
Cap/Sales 3.25%
Interest Coverage 250
Cash Conversion 138.93%
Profit Quality 144.77%
Current Ratio 3.67
Quick Ratio 3.27
Altman-Z 6.45
F-Score6
WACC7.86%
ROIC/WACC2.06
Cap/Depr(3y)76.88%
Cap/Depr(5y)63.55%
Cap/Sales(3y)2.83%
Cap/Sales(5y)2.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.9%
EPS 3Y77.08%
EPS 5Y34.43%
EPS Q2Q%-56.19%
EPS Next Y-20.69%
EPS Next 2Y-9.41%
EPS Next 3Y3.97%
EPS Next 5Y8.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-10.57%
Revenue Next Year23.02%
Revenue Next 2Y12.82%
Revenue Next 3Y10.55%
Revenue Next 5Y10.44%
EBIT growth 1Y-17.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.47%
EBIT Next 3Y8.62%
EBIT Next 5Y12.64%
FCF growth 1Y93.4%
FCF growth 3Y76.56%
FCF growth 5YN/A
OCF growth 1Y83.22%
OCF growth 3Y62.84%
OCF growth 5Y43.53%

ALKERMES PLC / ALKS FAQ

What is the fundamental rating for ALKS stock?

ChartMill assigns a fundamental rating of 6 / 10 to ALKS.


What is the valuation status of ALKERMES PLC (ALKS) stock?

ChartMill assigns a valuation rating of 6 / 10 to ALKERMES PLC (ALKS). This can be considered as Fairly Valued.


Can you provide the profitability details for ALKERMES PLC?

ALKERMES PLC (ALKS) has a profitability rating of 6 / 10.


Can you provide the expected EPS growth for ALKS stock?

The Earnings per Share (EPS) of ALKERMES PLC (ALKS) is expected to decline by -20.69% in the next year.